Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-0557
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK‑0557 is a highly selective, orally available small molecule antagonist of the neuropeptide Y5 receptor (NPY5R), with a Ki of approximately 1.6 nM. Neuropeptide Y (NPY) is an orexigenic neuropeptide involved in appetite regulation and energy homeostasis. By antagonizing the NPY5 receptor, MK‑0557 was developed as a potential anti-obesity agent and also investigated for cognitive impairment in schizophrenia. Despite reaching phase III clinical trials for obesity and being studied in phase II trials for cognitive dysfunction in schizophrenia, development was discontinued due to limited efficacy in weight loss or prevention of weight regain after diet-induced weight loss[1][2][3][4][5][6][7].
- Other names
- 328232-95-7AC-35453AC35453AC 35453DA-55513DA55513DA 55513FF158573FF-158573FF 158573HY-15411HY15411HY 15411MS-26961MS26961MS 26961N-[1-(2-fluorophenyl)pyrazol-3-yl]-1'-oxospiro[cyclohexane–4,3'-furo[3,4-c]pyridine]-1-carboxamide
02
Targets
NPY5R (Neuropeptide Y receptor type 5)
Beyond the preview
Go deeper on MK-0557.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-0557.